Scotiabank analyst George Farmer maintained a Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $21.86.
According to TipRanks, Farmer is a 4-star analyst with an average return of 16.0% and a 55.13% success rate. Farmer covers the Healthcare sector, focusing on stocks such as Legend Biotech, Tempest Therapeutics, and SAGE Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NewAmsterdam Pharma Company with a $37.00 average price target, a 69.26% upside from current levels. In a report released on May 8, RBC Capital also maintained a Buy rating on the stock with a $31.00 price target.
The company has a one-year high of $26.35 and a one-year low of $5.63. Currently, NewAmsterdam Pharma Company has an average volume of 218.9K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NewAmsterdam Pharma Company (NAMS) Company Description:
Frazier Lifesciences Acquisition Corp is a blank check company.
Read More on NAMS:
